• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy.

作者信息

Kuerer Henry M, Krishnamurthy Savitri, Rauch Gaiane M, Yang Wei T, Smith Benjamin D, Valero Vicente

机构信息

Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Ann Surg. 2018 Dec;268(6):e61-e62. doi: 10.1097/SLA.0000000000002573.

DOI:10.1097/SLA.0000000000002573
PMID:29064904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6056325/
Abstract
摘要

相似文献

1
Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy.新辅助全身治疗后乳腺癌患者手术切除的最佳选择
Ann Surg. 2018 Dec;268(6):e61-e62. doi: 10.1097/SLA.0000000000002573.
2
Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want.新辅助全身治疗后取消乳腺癌手术前的重要考量：倾听患者的需求。
Ann Oncol. 2020 Aug;31(8):1083-1084. doi: 10.1016/j.annonc.2020.04.009. Epub 2020 Apr 25.
3
Patients should be the tipping point of individualizing breast cancer surgery: Commentary on 'Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges'.患者应成为乳腺癌手术个体化的转折点：对《新辅助全身治疗后摒弃乳腺癌手术模式：当前证据与未来挑战》的评论
Ann Oncol. 2020 Sep;31(9):1264. doi: 10.1016/j.annonc.2020.05.021. Epub 2020 May 28.
4
Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.新辅助全身治疗后省略乳腺癌手术的进展
Ann Surg Oncol. 2022 Dec;29(13):7942-7944. doi: 10.1245/s10434-022-12455-7. Epub 2022 Aug 24.
5
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?现代乳腺癌新辅助治疗后的保乳治疗：我们正在错失良机吗？
Eur J Surg Oncol. 2016 Dec;42(12):1780-1786. doi: 10.1016/j.ejso.2016.10.011. Epub 2016 Oct 29.
6
Breast conservation following neoadjuvant therapy for breast cancer.乳腺癌新辅助治疗后的保乳治疗。
Minerva Chir. 2018 Jun;73(3):297-299. doi: 10.23736/S0026-4733.18.07727-1. Epub 2018 Mar 28.
7
[Evaluation of neoadjuvant therapy in breast carcinoma].[乳腺癌新辅助治疗的评估]
Chirurg. 2000 Dec;71(12):1458-65. doi: 10.1007/s001040051244.
8
Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.可手术乳腺癌患者新辅助化疗后的保乳手术
Ann Ital Chir. 2018;89:290.
9
[Option of the surgical mode for breast cancer based on the effect of neoadjuvant chemotherapy].基于新辅助化疗效果的乳腺癌手术方式选择
Nihon Geka Gakkai Zasshi. 2002 Nov;103(11):803-5.
10
Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients.T3期原发性肿瘤（>5厘米）患者的保乳手术与乳房切除术：对5685名医疗保险患者的回顾
Cancer. 2016 Jan 1;122(1):42-9. doi: 10.1002/cncr.29726. Epub 2015 Oct 19.

引用本文的文献

1
Treatment Changes in Breast Cancer Management and De-Escalation of Breast Surgery.乳腺癌治疗管理的变化与乳腺手术的降阶梯治疗
Eur J Breast Health. 2023 Jul 3;19(3):186-190. doi: 10.4274/ejbh.galenos.2023.2023-6-2. eCollection 2023 Jul.
2
Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.新辅助全身治疗后省略乳腺癌手术的进展
Ann Surg Oncol. 2022 Dec;29(13):7942-7944. doi: 10.1245/s10434-022-12455-7. Epub 2022 Aug 24.
3
Innovative Standards in Surgery of the Breast after Neoadjuvant Systemic Therapy.新辅助全身治疗后乳腺癌手术的创新标准
Breast Care (Basel). 2021 Dec;16(6):590-597. doi: 10.1159/000520051. Epub 2021 Nov 2.
4
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.可手术 HER2 阳性乳腺癌患者接受序贯与同期化疗治疗的无病生存和总生存：ACOSOG Z1041（Alliance）随机临床试验。
JAMA Oncol. 2019 Jan 1;5(1):45-50. doi: 10.1001/jamaoncol.2018.3691.

本文引用的文献

1
Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.新辅助全身治疗后浸润性乳腺癌的非手术治疗：概念基础和基本的国际可行性临床试验。
Ann Surg Oncol. 2017 Oct;24(10):2855-2862. doi: 10.1245/s10434-017-5926-z. Epub 2017 Aug 1.
2
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.新辅助全身治疗后可消除乳腺癌手术的例外响应者的临床可行性试验。
Ann Surg. 2018 May;267(5):946-951. doi: 10.1097/SLA.0000000000002313.
3
Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?新辅助化疗后乳腺癌的病理完全缓解能否通过微创活检来诊断？
Eur J Cancer. 2016 Dec;69:142-150. doi: 10.1016/j.ejca.2016.09.034. Epub 2016 Nov 4.